ALLR Allarity Therapeutics, Inc.
$1.22▼ -2.40%
Healthcare
Other
After hours
$1.18▼ -3.28%
Sep 11, 7:58 PM ET
Volume 194.4K
Avg Volume (10D) 95.3K
Key Metrics & Fundamentals
Market Cap
$19.41M
P/E Ratio
–
Div Yield
–%
52W Range
0.77 - 1.88
% vs 50 MA
-5.64%
% vs 200 MA
-1.85%
RSI-14
36.1
MACD Histogram
-0.0200
Beta (1Y vs SPY)
1.68
Free Cash Flow
-$2.56M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$2.42M
COGS
–
Operating Exp
$2.67M
Operating Income
-$2.67M
EBIT
-$2.67M
Pretax Income
-$3.41M
Net Income
-$3.41M
EPS (Diluted)
-0.21
Price & Volume History
Loading chart…
Recent News
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
GlobeNewswire · Sep 11, 2026 12:00 PM
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
GlobeNewswire · Aug 14, 2026 12:00 PM
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Zacks · Jul 22, 2026 1:40 PM
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
GlobeNewswire · Jul 7, 2026 12:00 PM
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?
Zacks · Jul 6, 2026 1:40 PM
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
GlobeNewswire · Jun 30, 2026 12:00 PM
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
Zacks · Jun 19, 2026 1:40 PM
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
GlobeNewswire · Jun 18, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
Mar 2026
See ALLR's money flow as a full page
Social Sentiment
No Reddit posts found for ALLR.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.